Molecular Medicine

, Volume 21, Issue 1, pp 536–543 | Cite as

Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment

  • Karin M. E. Andersson
  • Nicola Filluelo Cavallini
  • Dan Hu
  • Mikael Brisslert
  • Ron Cialic
  • Hadi Valadi
  • Malin C. Erlandsson
  • Sofia Silfverswärd
  • Rille Pullerits
  • Vijay K. Kuchroo
  • Howard L. Weiner
  • Maria I. Bokarewa
Research Article


T-helper cells producing interleukin (IL)-17A and IL-17F cytokines (Th17 cells) are considered the source of autoimmunity in rheumatoid arthritis (RA). In this study, we characterized specific pathogenic features of Th17 cells in RA. By using nano-string technology, we analyzed transcription of 419 genes in the peripheral blood CCR6+CXCR3 CD4+ cells of 14 RA patients and 6 healthy controls and identified 109 genes discriminating Th17 cells of RA patients from the controls. Th17 cells of RA patients had an aggressive pathogenic profile and in addition to signature cytokines IL-17, IL-23 and IL-21, and transcriptional regulators RAR-related orphan receptor gamma of T cells (RORγt) and Janus kinase 2 (JAK2), they produced high levels of IL-23R, C-C chemokine ligand type 20 (CCL20), granulocyte-monocyte colony-stimulating factor (GM-CSF) and transcription factor Tbet required for synovial homing. We showed that Th17 cells are enriched with Helios-producing Foxp3- and IL2RA-deficient cells, indicating altered regulatory profile. The follicular T-helper (Tfh) cells presented a functional profile of adaptor molecules, transcriptional regulator Bcl-6 and B-cell activating cytokines IL-21, IL-31 and leukemia inhibitory factor (LIF). We observed that anti-tumor necrosis factor (TNF) treatment had a limited effect on the transcription signature of Th17 cells. Patients in remission retained the machinery of receptors (IL-23R and IL-1R1), proinflammatory cytokines (IL-17F, IL-23, IL-21 and TNF) and adaptor molecules (C-X-C chemokine receptor 5 [CXCR5] and cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]), essential for efficient transdifferentiation and accumulation of Th17 cells. This study convincingly shows that the peripheral blood CCR6+CXCR3 CD4+ cells of RA patients harbor pathogenic subsets of Th17 and Tfh cells, which may transdifferentiate from Tregs and contribute to perpetuation of the disease.



This work was funded by grants from the Swedish Research Council (521-2011-2414 to M Bokarewa), the Swedish Association against Rheumatism, the King Gustaf Vth 80-year Foundation, Professor Nanna Swartz Foundation, the Torsten Söderberg’s Foundation, Rune and Ulla Amlövs Trust, the Ingabritt and Arne Lundberg’s Foundation, the University of Gothenburg, and the Regional agreement on medical training and clinical research between the Western Götaland county council and the University of Göteborg (ALFGBG-138661). M Bokarewa holds the Medical Society of Gothenburg Chair in Rheumatology (Ingrid Högbergs Fond). The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.


  1. 1.
    Miossec P, Korn T, Kuchroo VK. (2009) Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361:888–98.CrossRefGoogle Scholar
  2. 2.
    Koenders MI, et al. (2011) Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum. 63:2329–39.CrossRefGoogle Scholar
  3. 3.
    Stamp LK, James MJ, Cleland LG. (2004) Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol. Cell Biol. 82:1–9.CrossRefGoogle Scholar
  4. 4.
    Kotake S, et al. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345–52.CrossRefGoogle Scholar
  5. 5.
    Shen H, Goodall JC, Hill Gaston JS. (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60:1647–56.CrossRefGoogle Scholar
  6. 6.
    Kim J, Kang S, Kwon G, Koo S. (2013) Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann. Lab. Med. 33:52–9.CrossRefGoogle Scholar
  7. 7.
    Samson M, et al. (2012) Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64:2499–503.CrossRefGoogle Scholar
  8. 8.
    McGovern JL, et al. (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 64:3129–38.CrossRefGoogle Scholar
  9. 9.
    Chen DY, et al. (2011) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res. Ther. 13:R126.CrossRefGoogle Scholar
  10. 10.
    Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB, Koenders MI. (2013) The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders. BioDrugs. 27:439–52.CrossRefGoogle Scholar
  11. 11.
    Genovese MC, et al. (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum. 66:1693–704.CrossRefGoogle Scholar
  12. 12.
    Mease PJ, et al. (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370:2295–306.CrossRefGoogle Scholar
  13. 13.
    Genovese MC, et al. (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 72:863–9.CrossRefGoogle Scholar
  14. 14.
    Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S. (2013) Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells. 18:247–65.CrossRefGoogle Scholar
  15. 15.
    Valmori D, Raffin C, Raimbaud I, Ayyoub M. (2010) Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc. Natl. Acad. Sci. U. S. A. 107:19402–7.CrossRefGoogle Scholar
  16. 16.
    Yosef N, et al. (2013) Dynamic regulatory network controlling TH17 cell differentiation. Nature. 496:461–8.CrossRefGoogle Scholar
  17. 17.
    Lee Y, et al. (2012) Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13:991–9.CrossRefGoogle Scholar
  18. 18.
    Croxford AL, Mair F, Becher B. (2012) IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 42:2263–73.CrossRefGoogle Scholar
  19. 19.
    Zhou L, et al. (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 453:236–40.CrossRefGoogle Scholar
  20. 20.
    Kim CH. (2009) Migration and function of Th17 cells. Inflamm. Allergy Drug Targets. 8:221–8.CrossRefGoogle Scholar
  21. 21.
    Rivino L, et al. (2010) CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. J. Exp. Med. 207:565–77.CrossRefGoogle Scholar
  22. 22.
    Hirota K, et al. (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204:2803–12.CrossRefGoogle Scholar
  23. 23.
    Komatsu N, et al. (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20:62–8.CrossRefGoogle Scholar
  24. 24.
    Arnett FC, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–24.CrossRefGoogle Scholar
  25. 25.
    Prevoo ML, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38:44–8.CrossRefGoogle Scholar
  26. 26.
    Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. (2009) Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11:R123.CrossRefGoogle Scholar
  27. 27.
    Andersson SE, et al. (2012) Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 7:e47668.CrossRefGoogle Scholar
  28. 28.
    Perfetto SP, Chattopadhyay PK, Roederer M. (2004) Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4:648–55.CrossRefGoogle Scholar
  29. 29.
    Acosta-Rodriguez EV, et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–46.CrossRefGoogle Scholar
  30. 30.
    Liang SC, et al. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271–9.CrossRefGoogle Scholar
  31. 31.
    Kleinewietfeld M, et al. (2005) CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 105:2877–86.CrossRefGoogle Scholar
  32. 32.
    Takahashi R, et al. (2011) SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-γ and IL-17A production. J. Exp. Med. 208:2055–67.CrossRefGoogle Scholar
  33. 33.
    Knosp CA, et al. (2013) Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2. J. Immunol. 190:3235–45.CrossRefGoogle Scholar
  34. 34.
    Raffin C, et al. (2013) Human memory Helios-FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J. Immunol. 191:4619–27.CrossRefGoogle Scholar
  35. 35.
    Takatori H, et al. (2015) Helios enhances Treg cell function in cooperation with FoxP3. Arthritis Rheum. 67:1491–502.CrossRefGoogle Scholar
  36. 36.
    Bin Dhuban K, et al. (2015) Coexpression of TIGIT and FCRL3 identifies helios+ human memory regulatory T cells. J. Immunol. 194:3687–96.CrossRefGoogle Scholar
  37. 37.
    Morita R, et al.(2011) Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 34:108–21.CrossRefGoogle Scholar
  38. 38.
    Silver JS, Hunter CA. (2010) gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 88:1145–56.CrossRefGoogle Scholar
  39. 39.
    Hirota K, et al. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12:255–63.CrossRefGoogle Scholar
  40. 40.
    Sutton CE, Mielke LA, Mills KH. (2012) IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 42:2221–31.CrossRefGoogle Scholar
  41. 41.
    Yeste A, et al. (2014) IL-21 induces IL-22 production in CD4+ T cells. Nat. Commun. 5:3753.CrossRefGoogle Scholar
  42. 42.
    Sutton CE, et al. (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 31:331–41.CrossRefGoogle Scholar
  43. 43.
    Koenen HJ, et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 112:2340–52.CrossRefGoogle Scholar
  44. 44.
    Yang XO, et al. (2008) Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 29:44–56.CrossRefGoogle Scholar
  45. 45.
    Beriou G, et al. (2009) IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. 113:4240–9.CrossRefGoogle Scholar
  46. 46.
    Daley SR, Hu DY, Goodnow CC. (2013) Helios marks strongly autoreactive CD4+ T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-kappaB. J. Exp. Med. 210:269–85.CrossRefGoogle Scholar
  47. 47.
    Nie H, et al. (2013) Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat. Med. 19:322–8.CrossRefGoogle Scholar
  48. 48.
    Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. (2010) T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol. Rev. 237:72–89.CrossRefGoogle Scholar
  49. 49.
    Ma CS, Deenick EK, Batten M, Tangye SG. (2012) The origins, function, and regulation of T follicular helper cells. J. Exp. Med. 209:1241–53.CrossRefGoogle Scholar
  50. 50.
    Gottenberg JE, et al. (2012) Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann. Rheum. Dis. 71:1243–8.CrossRefGoogle Scholar
  51. 51.
    Choi YS, Yang JA, Crotty S. (2013) Dynamic regulation of Bcl6 in follicular helper CD4 T (Tfh) cells. Curr. Opin. Immunol. 25:366–72.CrossRefGoogle Scholar
  52. 52.
    Crotty S, Johnston RJ, Schoenberger SP. (2010) Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat. Immunol. 11:114–20.CrossRefGoogle Scholar
  53. 53.
    Atsumi T, et al. (2002) A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196:979–90.CrossRefGoogle Scholar
  54. 54.
    Sawa S, et al. (2006) Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. J. Exp. Med. 203:1459–70.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Karin M. E. Andersson
    • 1
  • Nicola Filluelo Cavallini
    • 1
  • Dan Hu
    • 2
  • Mikael Brisslert
    • 1
  • Ron Cialic
    • 2
  • Hadi Valadi
    • 1
  • Malin C. Erlandsson
    • 1
  • Sofia Silfverswärd
    • 1
  • Rille Pullerits
    • 1
  • Vijay K. Kuchroo
    • 2
  • Howard L. Weiner
    • 2
  • Maria I. Bokarewa
    • 1
  1. 1.Department of Rheumatology and Inflammation Research, Sahlgrenska University HospitalGothenburg UniversityGothenburgSweden
  2. 2.Center for Neurologic Diseases, Brigham & Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations